Global medical devices industry M&A deals total $413.18m in January 2020

Total medical devices industry M&A deals in January 2020 worth $413.18m were announced globally, according to GlobalData’s deals database.

The value marked a decrease of 84.7% over the previous month and a drop of 87.7% when compared with the last 12-month average, which stood at $3.37bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $353.18m. At the country level, the US topped the list in terms of deal value at $352.8m.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in January 2020 was the US with 22 deals, followed by Canada and China with one deal each.

In 2020, as of the end of January 2020, medical devices M&A deals worth $413.18m were announced globally, marking a decrease of 77.4% year on year.

Medical devices industry M&A deals in January 2020: Top deals

The top five medical devices industry M&A deals accounted for 96.6% of the overall value during January 2020.

The combined value of the top five medical devices M&A deals stood at $399.25m, against the overall value of $413.18m recorded for the month.

The top five medical devices industry deals of January 2020 tracked by GlobalData were:

  • Anika Therapeutics’ $100m acquisition of ArthroSurface
  • The $97m acquisition of NovaBone Products by Halma
  • Anika Therapeutics’ $95m acquisition of Parcus Medical
  • The $60m acquisition of LifeBond by CR Bard
  • Masimo’s asset transaction with NantHealth for $47.25m.

For more information 

To gain access to our latest press releases: GlobalData Media Centre 

Analysts are available for comment. Please contact the GlobalData Press Office:

EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809 


For expert analysis on developments in your industry, please connect with us on: 

GlobalData | LinkedIn | Twitter 

Notes to Editors 

This analysis considers only announced and completed deals from the GlobalData financial deals database and exclude all terminated and rumored deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage. 

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources. 

About GlobalData  4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis, and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, technology, energy, financial and professional services sectors.

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button